Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial

By Rob Curran

Biotech company Mersana Therapeutics said the Food and Drug Administration lifted a clinical hold on a Phase 1 trial of one of its cancer-treatment candidates.

In March, Mersana said the Food and Drug Administration had issued a clinical hold on the early-stage trial of the gastric-cancer drug candidate because of serious adverse effects.

Based on a review of data, Mersana lowered the starting dose in the Phase 1 dose escalation design, the company said.

In July, Mersana Therapeutics launched a broad restructuring following the failure of its lead product candidate in a late-stage study.

Write to Rob Curran at [e-mail]

(END) Dow Jones Newswires

10-31-23 0852ET